374 results about "Liver Cirrhoses" patented technology

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and / or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The invention relates to a drug combination of a multi-poly (ADP-ribose) polymerase (PARP) inhibitor, a method of treating or preventing HBV-related diseases by utilizing the drug combination, and the application of the drug combination. More specifically, the invention relates to a drug combination comprising 1-(ciprofloxacin formyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro benzoyl] piperazine, a method of treating or preventing HBV, liver cancer, liver cirrhosis and other HBV-related diseases by utilizing the drug combination, and the application of the drug combination.

The invention provides a composition containing at least one triterpene glucoside or an analogue, a metabolite, a precursor, a derivative, a medicinal active salt or a pre-drug thereof and application of the composition in preparing medicaments for treating and / or preventing viral infection. The invention also provides application of a joint composition consisting of the composition and a composition containing fluvastatin or an analogue, a metabolite, a derivative, a medicinal active salt, a precursor or a pre-drug thereof in preparing medicaments for treating and / or preventing viral infection. The composition and the method can be further used for preventing infection of subject patients or the attack and development of other disease symptoms related to viral infection of hepatitis C, such as liver cirrhosis, decompensatory liver diseases and / or hepatocellular carcinoma.

This invention provides a liver cirrhosis detection kit and detection method, and belongs to the biotechnology field. According to the detection method, anti-human chitinase 3 protein 1 (CHI3L1) antibody coats a microporous plate for preparation of a solid phase antibody, when in use, a to-be-tested sample is added into the microporous plate coated with the antibody, if the to-be-tested sample contains a tested matter, the to-be-tested sample can be combined on the solid phase antibody to form an antigen-antibody complex; then a biotin-labeled anti-human CHI3L1 antibody is added to form an antibody-antigen-biotin-labeled antibody complex; horse radish peroxidase (HRP)-labeled avidin is added to form an antibody-antigen-biotin-labeled antibody-enzyme labeled avidin complex; and finally the complex is added into 3, 3 ', 5, 5 '-tetramethyl benzidine substrate system for chromogenic reaction. After the chromogenic reaction is completed, an enzyme standard instrument is used or testing. The liver cirrhosis detection kit has the advantages of fast, simple and accurate determination of test results.